Les mitochondries sont des organites semi autonomes, capables d’autoréplication, qui varient en nombre, en taille et en forme dans le cytoplasme de presque toutes les cellules eucaryotes. Elles sont notamment connues pour être les fournisseurs d’énergie de la cellule. Afin de mener à bien ce rôle, les mitochondries sont capables de fusionner et de se diviser, ce qui permet un contrôle de la forme du réseau mitochondrial. Le contrôle de ces évènements et la forme du réseau qui en résulte sont connus sous le nom de dynamique mitochondriale. Cette dynamique répond à de nombreux stimuli cellulaires et est très régulée. Récemment, il a été montré que le système ubiquitine-protéasome régule la fusion des mitochondries et qu’une des sous unités du protéasome contrôlait la fission des mitochondries. Le système ubiquitine-protéasome est un mécanisme qui repose sur plusieurs acteurs : les enzymes qui vont reconnaître les protéines cibles de ce système, une protéine appelée ubiquitine qui sert pour le marquage des protéines cibles et un complexe multi-protéique appelé protéasome effecteur de la dégradation des protéines cibles. Connu uniquement à l’origine pour son rôle dans la dégradation des protéines cibles, il est apparu dans les dernières années que le rôle de ce système ou de ses composants en dehors de ce système était bien plus vaste. Les études effectuées au laboratoire avaient déjà montré que Rpn11, une sous-unité du protéasome, régulait la fission des mitochondries indépendamment de l’activité protéolytique du protéasome. Le travail présenté ici porte sur le mécanisme d’action du domaine C-terminal de Rpn11 sur divers processus cellulaires tels que l’assemblage du protéasome, la régulation de la fission des mitochondries et des peroxysomes, la longévité cellulaire ou la formation de « Proteasome Storage Granule ». Ce manuscrit présente aussi le travail effectué pour trouver les partenaires qui permettent la régulation de la fission des mitochondries avec le domaine C-terminal de Rpn11 ainsi que l’étude de la localisation in vivo de Rpn11. / Mitochondria are semi-autonomous organelles, which size, shape and number vary in a wide range in almost every eukaryotic cell. They are famous to be the energy producer of the cells. For this purpose, mitochondria are able to fuse and divide. These events of fusion and fission are also known as the mitochondrial dynamic. This phenomenon is highly controlled and answers to many stimuli. Lately, it has been shown that the ubiquitin proteasome system controls the fusion of mitochondria and that a proteasome subunit controls the mitochondrial fission. The ubiquitin proteasome system is a mechanism that relies on many actors: enzymes recognizing the targets of this system, a protein called ubiquitin and a complex called proteasome in charge of the degradation of the targets. Primarily known for the protein degradation, many investigations suggest that this system has other roles. Our previous studies had already shown that the proteasome subunit named Rpn11 controls the fission of mitochondria independently of the proteolytic activities of the proteasome system. The work shown in this manuscript is focused on the mechanism of action of the C-terminus domain of Rpn11 on various cellular processes, including proteasome assembly, control of mitochondrial and peroxisomal fission, yeast lifespan and also the “Proteasome Storage Granule” formation. The in vivo localisation of Rpn11 and the elucidation of its partners on the mitochondrial fission regulation were also investigated.

A distrofia muscular progressiva no cão Golden Retriever (GRMD) é uma miopatia genética homóloga à Distrofia Muscular de Duchenne (DMD) que acomete humanos. A utilização do modelo canino é considerada ideal uma vez que a progressão da doença, as manifestações clínicas e a massa corporal se assemelham às apresentadas por meninos doentes. Sabe-se que a degradação de proteínas musculares e atrofia muscular estão intimamente relacionadas com a atuação do sistema catalítico ubiquitina-proteassoma. Estudos utilizando camundongos com distrofia muscular e músculos de humanos DMD (in vitro) tratados com inibidores de proteassoma (MG-132 e bortezomibe) apresentaram restauração da distrofina e das proteínas associadas à distrofina e melhora do fenótipo histopatológico. Nesta pesquisa, foram avaliados cinco cães GRMD, dois tratados com Bortezomibe e três controles. Coletou-se biopsia muscular antes de iniciar o tratamento e ao término do mesmo, para os testes de histologia, ultraestrutura e imunohistoquímica. Foram realizados semanalmente testes bioquímicos e em cada ciclo de aplicação do bortezomibe foi mensurada a taxa de inibição do proteassoma. Na primeira biopsia todos os cães apresentaram morfologia histopatológica das fibras musculares semelhantes. Ao final do tratamento, os cães tratados apresentaram menor deposição de tecido conjuntivo e infiltração de células inflamatórias que os cães não tratados julgados por meio da histologia, morfometria do colágeno e ultraestrutura. Na ultraestrutura observamos infiltração de macrófagos nas fibras, material degenerado, fibroblastos ativados e deposição e tecido conjuntivo em endomísio e perimísio das fibras. Pela análise de imunohistoquímica, não constatamos presença de distrofina na membrana sarcoplasmática de ambos os grupos avaliados. Entretanto, os cães tratados apresentaram maior expressão das proteínas α e β distroglicano, o que sugere uma melhora no fenótipo histopatológico da doença. Nos cães não tratados observou-se maior expressão de phospho- NFκB e TGF-β1 sugerindo maior ativação de fatores pró-apoptóticos e moléculas inflamatórias, e maior deposição de tecido conjuntivo, respectivamente. Os testes de inibição do proteassoma indicaram maior inibição nas células sanguíneas uma hora após a aplicação do bortezomibe e estes de comportaram de forma dose-dependente. Concluímos que os inibidores de proteassoma podem melhorar a morfologia das fibras musculares dos cães GRMD tratados, diminuindo a deposição de colágeno e infiltração de células inflamatórias, bem como restaurar parte das proteínas associadas à distrofina na membrana sarcoplasmática das fibras musculares. / The Golden Retriever Muscular Dystrophy (GRMD) is a genetic myopathy homologue to Duchenne Muscular Dystrophy (DMD) in human. Use of canine model is the better because the disease development, clinical signs and body mass are closed to the sick children. It has been known muscle protein proteolysis and muscle atrophy are related with ubiquitin-proteasome pathway. Researches using mdx mice and human muscle (in vitro) treated with proteasome inhibitor (MG-132 and bortezomib) showing rescue of the dystrophin and associated proteins and improvement of histopatologycal phenotype. In this research, were analyzed five GRMD dogs, two dogs were treated with Bortezomib and three dogs were control. Muscle biopsies were collected before the treatment and after the treatment to histology, ultrastructure and immunohistochemical muscle analysis. Biochemistry analyses were made once a week and measurement of proteasome inhibition was analysed in each cycle of Bortezomib administration. In the first byopsy, all the dogs showing closed histophatological morphology of muscle fibers. At the end of treatment, the treated dogs had lower connective tissue deposition and inflammatory cells infiltration than untreated dogs by histology, collagen morphometry and ultrastructural analysis. We noted by ultrastructural analysis macrophages inside the fibers, degenerated products, activated fibroblasts and connective tissue deposition in edomisium and perimisium of the fibers. The dystrophin immunohistochemistry was not presence in sarcoplasmatic membrane in both groups. However, the treated dogs showing bigger expression of α and β-dystroglycan, this fact means improved of disease histopathology phenotype. The untreated dogs had bigger expression of phospho-NFκB and TGF-β1, suggesting bigger activation of pro-apoptotic factors, inflammatory molecules and bigger connective tissue deposition respectively. The proteasome inhibition tests indicated bigger inhibition in the blood cells one hour post doses of bortezomib and was dose-dependent pathway. In conclusion, the proteasome inhibitors may improve the appearance of GRMD muscle fibers, lowered the connective tissue deposition and infiltration of inflammatory cells, likewise to rescue the dystrophin- associated proteins in the muscle fiber membrane.

Nas células eucariotas a maioria das proteínas citoplasmáticas não são degradadas nos lisossomas, mas em organelas altamente conservadas encontradas em humanos, arquibactérias, plantas e leveduras, os proteassomas. Esta estrutura multicatalítica é constituída por componentes menores, cujo núcleo funcional é o componente 20S, que contém várias atividades proteolíticas (tríptica, quimotríptica, de peptidilglutamil peptidase, BrAAP e SNAAP). Esse componente 20S, associado ao complexo regulatório 19S, que é composto de múltiplas ATPases, forma o complexo 26S, responsável pela degradação de proteínas conjugadas com a ubiquitina. Estas estruturas citosólicas certamente desempenham papel importante no desenvolvimento de protozoários parasitas e na sua interação com células dos hospedeiros permissivos. Nesta dissertação, apresentamos um estudo sobre o papel do proteassoma na interação e desenvolvimento de promastigotas de Leishmania chagasi em macrófagos murinos. Inicialmente, purificamos e caracterizamos parcialmente o proteassoma de promastigotas de L. chagasi. Observamos que o complexo presente na L. chagasi possui atividades proteolíticas frente a pelo menos dois substratos sintéticos, LLVY-AMC e LRR-AMC, que avaliam, respectivamente, as atividades quimiotripsina-símile e tripsina-símile. A atividade tripsina-simile é maior que a atividade quimiotripsina-simile; e além disso, esta última é totalmente inibida pela lactacistina, um inibidor específico do proteassoma, enquanto a atividade tripsina-simile é apenas parcialmente inibida. Utilizando a lactacistina foi possível analisar o papel desse complexo proteolítico durante a infecção e desenvolvimento intracelular da L. chagasi. Promastigotas mantidas em cultura na presença de 50μM de lactacistina tiveram seu crescimento bloqueado. Essas promastigotas eram capazes de infectar macrófagos peritoneais de camundongos BALB/c, mas não conseguiam sobreviver dentro desses macrófagos. Esta incapacidade de sobrevivência foi específica para os parasitas tratados com a lactacistina, não sendo observado nos parasitas tratados com outros inibidores de proteases. Estes resultados sugerem que o proteassoma pode ter um papel importante no desenvolvimento intracelular e na replicação das promastigotas de L. chagasi no hospedeiro vertebrado. / Proteasomes are multicatalitic and multisubunit endopeptidase complexes widely distributed in eukaryotic cells. These enzymes are central proteases in the cytosol and nucleus and are involved in removal of abnormal, misfolded or incorrectly assembled proteins, in processing and degradation of transcriptional regulators in stress response and in the processing of protein antigens. This multicatalytic proteinase complex is composed of a catalytic core, 20S proteasome, which have multiple proteolytic activities (trypsin-like, chymotrypsin-like, peptidylglutamtyl-peptide hydrolyzing, BrAAP and SNAAP). The 20S proteasome associates with the multisubunit complex 19S to produce the 26S proteasome. The 26S proteasome has specificity for ubiquitinylated protein substrates and hydrolyses ATP during proteolysis of ubiquitinylated proteins. In the present work we have purified a 20S form of proteasome from Leishmania chagasi and partially characterized it. The purified 20S proteasome has activity towards fluorogenic substrates that are cleaved by trypsin or chymotrypsin, and is sensitive to lactacystin, a specific inhibitor of the proteasome. We show that the L.chagasi proteasome the trypsin-like activity is higher than the chymotrypsin-like. Therefore the chymotrypsin-like activity is inhibited by lactacystin and the trypsin-like it is only partially inhibited. We show here that lactacystin blocks in vitro L chagasi promastigote replication at a final concentration of 50 µM. To evaluate the effect of proteasome inhibition on the infectivity and intracellular development of L. chagasi, murine macropages were challenged with promastigotes from early stationary phase treated with lactacystin. Infectivity of macrophages was the same in lactacystin-treated parasites as in the untreated ones. Contrarywise, the intracellular development of the parasite is impaired by pretreating promastigotes with lactacystin. These promastigotes were able to infect BALB/c peritoneal macrophages but they did not survive inside macrophages. These data indicate the important role of the proteasomes of L. chagasi promastigotes on the intracellular development and replication in host cells in vitro.

Although all cells in a multicellular organism contain the same set of genes, the spatiotemporal expression of these genes needs to be dynamically regulated for morphogenesis and life cycle transitions to take place. Polycomb-group (PcG) proteins are evolutionarily-conserved epigenetic regulators that function – via epigenetic marks such as H3K27me3 and modifications to chromatin structure – to maintain the repression of developmentally-important genes so that these genes are only expressed in the appropriate cells at the appropriate times. This repressive activity of the PcG is antagonised by the trithorax-group (trxG) of proteins. Although they maintain specific patterns of gene repression, PcG proteins are ubiquitously expressed. How their activity is regulated is largely unknown. To identify such regulatory pathways, a genetic screen for modifiers of PcG activity in Arabidopsis was carried out previously using the PcG mutant curly leaf (clf), which has moderately-severe developmental defects due to the ectopic or untimely expression of developmental regulators such as floral homeotic genes and the important flowering time regulator FLOWERING LOCUS T (FT). I characterised three novel potential regulators identified in this genetic screen: the chromatin-associated protein AT-HOOK MOTIF NUCLEAR LOCALISED PROTEIN 22 (AHL22), the 26S proteasome and the novel trithorax-group members ANTAGONIST OF LHP1 1 and 2 (ALP1 and ALP2). I found that the dominant sop-11D mutation is caused by over expression of AHL22 which suppresses the phenotype of clf by reducing FT expression. However, genetic analysis suggests that AHL22 may act in a parallel pathway to the PcG. I showed that mutations affecting diverse subunits of the 26S proteasome reduce the mis-expression of CLF targets and suppress the phenotypes of clf although they do not restore H3K27me3 levels at these targets. Pharmacological inhibition of the proteasome also alleviated the mis-expression of target genes found in clf mutants. Analysis of PcG protein levels following proteasome inhibition suggests that the 26S proteasome antagonises the PcG by degrading the key PcG member EMBRYONIC FLOWER 1 (EMF1), which is likely to be important for implementing target gene repression. Surprisingly, my proteomic analysis showed that the novel trxG members ALP1 and ALP2 are accessory components of a core PcG complex – the Polycomb Repressive Complex 2 (PRC2) – in vivo, suggesting that that ALP1 and ALP2 may antagonise PcG repression by preventing the association of core PRC2 components with accessory components EMF1, LIKE HETEROCHROMATIN PROTEIN 1 and the PHD finger proteins VERNALISATION5 and VIN3-LIKE 1. My results reveal a previously unknown role for 26S proteasomal degradation in the regulation of PcG activity during vegetative development and identify novel in vivo associators of the core PRC2 and point to their role in modulating PcG activity. These results thereby increase our understanding of how the PcG is regulated and serve as a starting point to discover how specificity is given to the PcG mediated repression, either by targeted degradation of EMF1 by various E3 ligases or by different combinations of PRC2 associators.

O proteassomo é uma protease intracelular multimérica e multicatalítica responsável pela degradação de proteínas envolvidas no controle do ciclo celular, processos de sinalização, apresentação antigênica e no controle de síntese proteica. Ele é constituído por uma unidade catalítica central denominada 20S (20SPT) e por unidades regulatórias (19S) acopladas em uma ou ambas as extremidades para formar o 26S (26SPT). O 26SPT reconhece e direciona os substratos poliubiquitinados para a proteólise por um mecanismo dependente de ATP. Entretanto, o 20SPT também é ativo quando dissociado de unidades regulatórias, degradando proteínas independentemente de poliubiquitinação e consumo de ATP. Proteínas modificadas oxidativamente e outros substratos são degradados desta maneira. O 20SPT é composto por dois anéis heptaméricos centrais (β) onde estão localizados os sítios catalíticos e por dois anéis heptaméricos externos (α) que são responsáveis pela abertura da câmara catalítica. Anteriormente, foi observado pelo grupo que o 20SPT da levedura S.cerevisiae sofre S-glutatiolação na subunidade α5 nos resíduos de Cys76 e Cys221. Assim, foram obtidas neste projeto linhagens de levedura S. cerevisiae portando mutações sítio-específicas na subunidade α5 do 20SPT (α5-C76S ou α5-C221S), e posteriormente, ensaios comparativos quanto às consequências estruturais e funcionais dessas mutações foram realizados. Observamos um aumento na capacidade/velocidade de degradação nas atividades peptidásicas e proteolíticas da mutante C221, e também que, a população de proteassomo isolada dessa linhagem apresenta maior proporção da forma aberta da câmara catalítica, sendo esta imediatamente fechada pela remoção da glutationa do 20SPT na presença de DTT. Resultados opostos foram observados na linhagem mutante C76. Identificamos por espectrometria de massas o resíduo C76 do 20SPT glutationilado na mutante C221. Os ensaios fenotípicos mostraram um aumento da longevidade e resistência ao estresse oxidativo da C221, enquanto que a linhagem C76 mostrou uma dificuldade no crescimento. Contudo, a S-glutationilação do 20SPT é uma modificação química pós-traducional reversível de ocorrência fisiológica dependente do estado redox celular, e, o presente trabalho discute a modulação da câmara catalítica do 20SPT através da S-glutationilação de dois resíduos de cisteína localizados na subunidade α5, e as consequências desta modificação na função proteassomal / The proteasome is a multimeric and multicatalytic intracellular protease responsible for the degradation of proteins involved in cell cycle control, signaling processes, antigen presentation, and control of protein synthesis. It comprises a central catalytic unit called 20S (20SPT) and regulatory units (19S) coupled at one or both ends to form 26S (26SPT). The 26SPT recognizes and directs polyubiquitinylated substrates targeted for proteolysis by an ATP-dependent mechanism. However, 20SPT is also active when dissociated from regulatory units, degrading proteins by a process independent of polyubiquitinylation and ATP consumption. Oxidatively modified proteins and other substrates are degraded in this manner. The 20SPT comprises two central heptamerics rings (β) where are located the catalytic sites and two external heptamerics rings (α) that are responsible for proteasomal gating. Previously, it was observed by our group that the 20SPT of yeast S. cerevisiae is modified by S-glutathionylation in the residues Cys76 and Cys221 of the α5 subunit. Thus, were obtained in this project strains of the S. cerevisiae carrying site-specific mutations in the α5 subunit of the 20SPT (α5-C76S or α5-C221S), and comparative assays as the structural and functional consequences of these mutations were performed. We observed an increase in capacity/speed of degradation in peptidase and proteolytic activity in the C221 strain and also that, the isolated population of the proteasome this strain presents the highest frequency of open catalytic chamber conformation, which is immediately closed by the removal of glutathione of the 20SPT in the presence of DTT. Opposite results were observed in the C76 strain. We identified by mass spectrometry the C76 residue of the 20SPT glutathionyilated the C221 mutant. Phenotypic assays show an increased longevity and resistance to oxidative stress of C221, while the C76 strain showed a difficulty in growth. However, the S-glutathionylation of the 20SPT is a reversible post-translational chemical modification of physiological occurrence dependent on the cellular redox state, and this project discusses the modulation of the catalytic chamber of 20SPT via S-glutationylation of the two cysteine residues located the α5 subunit, and the consequences of this change in proteosomal function

Emerging evidence indicates that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression in transgenic mouse models of solid human cancers, but the potential of integrated FDG-PET/CT for assessing tumor development in genetically engineered mouse models of liquid human cancers - including neoplasms of immunoglobulin (Ig)-producing plasma cells - has not been established. Here we use a double-transgenic strain of laboratory mice, designated C.IL6Myc, that recapitulates key features of human plasma cell myeloma (a.k.a. multiple myeloma [MM]) to demonstrate that FDG-PET/CT affords a useful research tool for assessing plasma cell tumor (PCT) development in a serial, objective and, importantly, stage- and lesion-specific manner. Supported by serum biomarker analyses (Ig level, paraprotein) and histopathological findings in C.IL6Myc mice undergoing PCT development, the newly generated FDG-PET/CT data set demonstrates the potential of this imaging modality for preclinical basic and translational MM research. PET imaging of genetically engineered mice in which MM-like tumors arise predictably in an intact immunocompetent microenvironment may facilitate the design and testing of new approaches to the treatment and prevention of MM in humans.

Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and ixazomib, have contributed to a significant improvement in the overall survival for multiple myeloma (MM) patients. However, the response rate of PI was fairly low, leaving a huge gap in MM patient care. Given this, mechanistic understanding of PI resistance is crucial towards developing new therapeutic strategies for refractory/relapsed MM patients. In this dissertation work, we found H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS). It indicated H727 cells may serve as a cell line model for de novo Cfz resistance and remains UPS dependent for survival. To examine the potential link between proteasome catalytic subunit composition and cellular response to Cfz, we altered the composition of proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown in H727 cells. Our results showed alteration in composition of proteasome catalytic subunits results in sensitization of H727 cells to Cfz. It supported that proteasome inhibition by alternative PIs may still be a valid therapeutic strategy for patients with relapsed MM after having received treatment with Cfz. With this in mind, we designed and synthesized a small library of epoxyketone-based PIs by structural modifications at the P1′ site. We observed that a Cfz analog, harboring a hydroxyl substituent at its P1′ position was cytotoxic against cancer cell lines with de novo or acquired resistance to Cfz. These results suggested that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to overcome Cfz resistance mechanisms in cells. The immunoproteasome (IP), an inducible proteasome variant which is harboring distinct catalytic subunits, LMP2, MECL1 and LMP7 of the proteasome typically expressed in cells of hematopoietic origin, plays a role in immune response and is closely linked to inflammatory diseases. It has been reported that the IP is upregulated in reactive glial cells surrounding amyloid β (Aβ) deposits in brains of Alzheimer’s disease (AD) patients and AD animal models. To investigate whether the IP is involved in the pathogenesis of AD, we examined the impact of IP inhibition on cognitive function in AD mouse models. We observed that YU102, an epoxyketone peptide targeting the IP catalytic subunit LMP2, improved cognitive dysfunction in AD mice without clearance of Aβ deposition or tau aggregation. Our cell line model study also showed a potential mode of action of YU102 which is suppressing pro-inflammatory cytokine production in microglial cells. It suggested that LMP2 contributes to microglia-mediated inflammatory response. These findings supported that LMP2 may offers a valuable therapeutic target for treatment of Alzheimer’s disease, expanding the therapeutic potential of the LMP2-targeting strategy.

The proteasome is a major non-lysosomal proteolytic complex present in eukaryotic cells and has a central role in regulating many protein levels. The complex has been shown to participate in various intracellular pathways including cell cycle regulation or quality control of newly synthesized proteins and many other key pathways. This amazing range of substrates would not be possible without the help of regulators that are able to bind to the 20S proteasome and modulate its activity. Among those, the PA700 or 19S regulator and the PA28 family are the best characterized in higher eukaryotes. The 19S regulatory particle is involved in the recognition of ubiquitinated proteins, targeted for degradation by the proteasome. The PA28 (also termed 11S REG) family is composed of two members the PA28αβ and PA28γ. The function of PA28αβ is related to the adaptive immune response with a proposed contribution in MHC class I peptide presentation whereas the biological role PA28γ remains unknown. The main objectives of the laboratory, and subsequently of this thesis are to use Drosophila melanogaster model system and its advantages to better understand the precise contribution of these different activators in the regulation of the proteasome. Using genomic resources, a unique Drosophila PA28 member was identified, characterized and was shown to be a proteasome regulator with all the properties of PA28γ. Through site-directed mutagenesis we identified a functional nuclear localization signal in the homolog-specific insert region. Study of the promoter region revealed that transcription of Drosophila PA28γ (dPA28γ) gene is under control of DREF, a transcription factor involved in the regulation of genes related to DNA synthesis and cell proliferation. To confirm that dPA28γ has a role in cell cycle progression, the effect of removing dPA28γ from S2 cells was tested using RNA interference. Drosophila cells depleted of dPA28γ showed partial arrest in G1/S cell cycle transition confirming a conserved function between Drosophila and mammalian forms of PA28γ. Finally, characterization of the Dictyostelium regulator, an evolutionarily distant member of the PA28γ, was carried out using fluorogenic degradation assays. We are currently knocking-out the gene in order to determine the biological function of the activator. A second part of my work consisted in the generation of a Drosophila assay used to identify in vivo substrates of the 19S regulator, an assay system that has been originally engineered by Dantuma and coworkers in human cell lines. This was achieved by cloning of GFP behind a series of modified ubiquitins that create substrates degraded through different pathways involving the proteasome pathways. The last project of my thesis concerns the characterization of the mechanism for upregulation of proteasomal gene mRNA after MG132 (proteasome inhibitor) treatment. So far, we found that the 5´-UTR of the genes is responsible for this induction. We are now looking for the precise motif involved in this regulation.

Retinoic acid (RA) has been recognized as a chemotherapeutic agent for various malignances such as lung, skin as well as cervical cancers. It binds to retinoid receptors heterodimers and consequently activates several RA-responsive genes which are involved in many biological processes including vertebrate development, bone growth, vision, haematopoiesis, cell growth, differentiation and apoptosis. These genes are under the control of numerous regulators to ensure their timely ordered activities. Among these regulators, we focused here on the 26S proteasome and ubiquitination. It has been reported that the activity of the ubiquitin/proteasome system (UPS) plays a fundamental role in retinoic acid receptor (RAR)-regulated transactivation. The mechanisms underlying this role, however, remain to be established. Chromatin immunoprecipitation (ChIP) assays in our study demonstrated that the 26S proteasome activity is important for preserving the occupancy of a TATA box-containing RA-responsive promoters by liganded retinoid receptors and thus by their coactivators. Additionally, by using coimmunoprecipitation assays and by measuring the half-life of retinoid receptors, we found that the non-proteolytic function of the proteasome is required for ligand-dependent association between DNA-free RAR-α and both DNA-free RXR-α and coactivators. Moreover, using immunofluorescent staining and in vivo ubiquitination assays, a proteasome inhibition-dependent cytoplasmic localization of RAR-α as well as ligand-enhanced ubiquitination and stabilization of RAR-α were shown. Our findings therefore, define novel mechanisms by which the UPS controls RAR-regulated genes. Furthermore, we shed new light on the regulators of retinoid receptors ubiquitination and subcellular localization.

The USP4 is a deubiquitinating enzyme found elevated in certain human lung and adrenal tumours. USP4 has a very close relative, USP15, which has caused great difficulty in studying only one or the other. We have had generated two antibodies specific to USP4 and USP15, and have confirmed that the two do not cross react. Although there have been previous findings of interacting partners, possible substrates and pathways in which it is involved, the biological role of USP4 is mostly unknown. We have used these antibodies to determine that USP4 and USP15 expression differs across tissue and cell types, and that expression changes as the organism ages. We have shown that USP4 plays a role in canonical Wnt signaling, perhaps by stabilizing Beta-catenin, and identified GRK2 as a kinase, phosphorylating USP4. These data have provided enough information to form a hypothesis, implicating USP4 with the destruction complex in the Wnt signaling pathway.